Advances in biologic and small molecule therapies for hidradenitis suppurativa

References

• Jfri A, Nassim D, O’Brien E, et al. Prevalence of hidradenitis suppurativa: a systematic review and meta-regression analysis. JAMA Dermatol. 2021;157(8):924–931.
   PubMed Web of Science ®Google Scholar
• Kimball AB, Sobell JM, Zouboulis CC, et al. HiSCR (Hidradenitis suppurativa clinical response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo‐controlled portion of a phase 2 Adalimumab study. J Eur Acad Dermatol Venereol. 2016;3(6):989.
   Google Scholar
• Zouboulis CC, Tzellos T, Kyrgidis A, et al. Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity. Br J Dermatol. 2017;177(5):1401–1409.
   PubMed Web of Science ®Google Scholar
• Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–216.
   PubMed Web of Science ®Google Scholar
• Hawker GA, Mian S, Kendzerska T, et al. Measures of adult pain: visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res (Hoboken). 2011;63(11):S240–52.
   PubMed Web of Science ®Google Scholar
• Yosipovitch G, Reaney M, Mastey V, et al. Peak pruritus numerical rating scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. Br J Dermatol. 2019;181(4):761–769.
   PubMed Web of Science ®Google Scholar
• Horiuchi T, Mitoma H, Harashima SI, et al. Transmembrane TNF-: structure, function and interaction with anti-TNF agents. Rheumatology. 2010;49(7):1215–1228.
   PubMed Web of Science ®Google Scholar
• Matusiak L, Bieniek A, Szepietowski J. Increased serum tumour necrosis factor- in hidradenitis suppurativa patients: is there a basis for treatment with anti-tumour necrosis factor- agents? Acta Derm Venereol. 2009;89(6):601–603.
   PubMed Web of Science ®Google Scholar
• Mozeika E, Pilmane M, Nürnberg B, et al. Tumour necrosis factor-alpha and matrix metalloproteinase-2 are expressed strongly in hidradenitis suppurativa. Acta Derm Venereol. 2013;93(3):301–304.
   PubMed Web of Science ®Google Scholar
• van der Zee HH, de Ruiter L, van den Broecke DG, et al. Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β. Br J Dermatol. 2011;164(6):1292–1298.
   PubMed Web of Science ®Google Scholar
• van der Zee HH, Laman JD, de Ruiter L, et al. Adalimumab (antitumour necrosis factor-α) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study. Br J Dermatol. 2012;166(2):298–305.
   PubMed Web of Science ®Google Scholar
• Humira (Adalimumab) [Package Insert]. North Chicago IL: AbbVie Inc.; 2021.
   Google Scholar
• Mould DR, Dubinsky MC. Dashboard systems: pharmacokinetic/pharmacodynamic mediated dose optimization for monoclonal antibodies. J Clin Pharmacol. 2015;55(S3):S51–S59.
   PubMedGoogle Scholar
• Weisman MH, Moreland LW, Furst DE, et al. Efficacy, pharmacokinetic, and safety assessment of Adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther. 2003;25(6):1700–1721.
   PubMed Web of Science ®Google Scholar
• Kimball AB, Okun MM, Williams DA, et al. Two phase 3 trials of Adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375(5):422–434.
   PubMed Web of Science ®Google Scholar
• Ternant D, Paintaud G. Pharmacokinetics and concentration–effect relationships of therapeutic monoclonal antibodies and fusion proteins. Expert Opin Biol Ther. 2005;5(sup1):S37–S47.
   PubMed Web of Science ®Google Scholar
• Miller I, Lynggaard CD, Lophaven S, et al. A double-blind placebo-controlled randomized trial of Adalimumab in the treatment of hidradenitis suppurativa. Br J Dermatol. 2011;165(2):391–398.
   PubMed Web of Science ®Google Scholar
• Arenbergerova M, Gkalpakiotis S, Arenberger P. Effective long-term control of refractory hidradenitis suppurativa with Adalimumab after failure of conventional therapy. Int J Dermatol. 2010;49(12):1445–1449.
   PubMed Web of Science ®Google Scholar
• Kimball AB, Kerdel F, Adams D, et al. Adalimumab for the treatment of moderate to severe hidradenitis suppurativa. Ann Intern Med. 2012;157(12):846.
   PubMed Web of Science ®Google Scholar
• Zouboulis CC, Okun MM, Prens EP, et al. Long-term Adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study. J Am Acad Dermatol. 2019;80(1):60–69.e2. DOI:https://doi.org/10.1016/j.jaad.2018.05.040.
   PubMed Web of Science ®Google Scholar
• Morita A, Takahashi H, Ozawa K, et al. Twenty‐four‐week interim analysis from a phase 3 open‐label trial of Adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa. J Dermatol. 2019;46(9):745–751.
   PubMed Web of Science ®Google Scholar
• Morita A, Takahashi H, Ozawa K, et al. Long‐term analysis of Adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa: open‐label phase 3 results. J Dermatol. 2021;48(1):3–13.
   PubMed Web of Science ®Google Scholar
• Remicade (Infliximab) [Package Insert]. Horsham PA: Janssen Biotech, Inc.; 2013.
   Google Scholar
• Ordás I, Mould DR, Feagan BG, et al. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther. 2012;91(4):635–646.
   PubMed Web of Science ®Google Scholar
• Klotz U, Teml A, Schwab M. Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet. 2007;46(8):645–660.
   PubMed Web of Science ®Google Scholar
• Dotan I, Ron Y, Yanai H, et al. Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease. Inflamm Bowel Dis. 2014;20(12):2247–2259.
   PubMed Web of Science ®Google Scholar
• Fasanmade AA, Adedokun OJ, Olson A, et al. Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis. Int J Clin Pharmacol Ther. 2010;48(5):297–308.
   PubMed Web of Science ®Google Scholar
• Grant A, Gonzalez T, Montgomery MO, et al. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol. 2010;62(2):205–217. DOI:https://doi.org/10.1016/j.jaad.2009.06.050.
   PubMed Web of Science ®Google Scholar
• Moriarty B, Jiyad Z, Creamer D. Four-weekly infliximab in the treatment of severe hidradenitis suppurativa. Br J Dermatol. 2014;170(4):986–987.
   PubMed Web of Science ®Google Scholar
• Ghias MH, Johnston AD, Kutner AJ, et al. High-dose, high-frequency infliximab: a novel treatment paradigm for hidradenitis suppurativa. J Am Acad Dermatol. 2020;82(5):1094–1101.
   PubMed Web of Science ®Google Scholar
• Oskardmay AN, Miles JA, Sayed CJ. Determining the optimal dose of infliximab for treatment of hidradenitis suppurativa. J Am Acad Dermatol. 2019;81(3):702–708.
   PubMed Web of Science ®Google Scholar
• Paradela S, Rodríguez-Lojo R, Fernández-Torres R, et al. Long-term efficacy of infliximab in hidradenitis suppurativa. J Dermatolog Treat. 2012;23(4):278–283.
   PubMed Web of Science ®Google Scholar
• Enbrel (Etanercept) [Package Insert]. Thousand Oaks CA: Immunex Corporation; 2020.
   Google Scholar
• Zhou H. Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein. J Clin Pharmacol. 2005;45(5):490–497.
   PubMed Web of Science ®Google Scholar
• Goffe B, Cather JC. Etanercept: an overview. J Am Acad Dermatol. 2003;49(2):105–111.
   PubMed Web of Science ®Google Scholar
• Giamarellos-Bourboulis EJ, Pelekanou E, Antonopoulou A, et al. An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa. Br J Dermatol. 2007;158(3):567–572.
   PubMedGoogle Scholar
• Lee RA, Dommasch E, Treat J, et al. A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa. J Am Acad Dermatol. 2009;60(4):565–573.
   PubMed Web of Science ®Google Scholar
• Adams DR, Yankura JA, Fogelberg AC, et al. Treatment of hidradenitis suppurativa with etanercept injection. Arch Dermatol. 2010;146(5). DOI:https://doi.org/10.1001/archdermatol.2010.72
   Google Scholar
• Cimzia (Certolizumab Pegol) [Package Insert]. Smyrna GA: UCB, Inc.; 2017.
   Google Scholar
• Mahadevan U, Wolf DC, Dubinsky M, et al. Placental transfer of anti–tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11(3):286–292.
   PubMed Web of Science ®Google Scholar
• Marchioni RM. Tumor necrosis factor-α inhibitor therapy and fetal risk: a systematic literature review. World J Gastroenterol. 2013;19(17):2591.
   PubMed Web of Science ®Google Scholar
• Porter ML, Golbari NM, Lockwood SJ, et al. Overview and update on biologic therapy for moderate-to-severe hidradenitis suppurativa. Semin Cutan Med Surg. 2018;37(3):182–189.
   PubMedGoogle Scholar
• Wohlmuth‐Wieser I, Alhusayen R. Treatment of hidradenitis suppurativa with certolizumab pegol during pregnancy. Int J Dermatol. 2021;60(4). DOI:https://doi.org/10.1111/ijd.15286
   Google Scholar
• Holm JG, Jørgensen AR, Yao Y, et al. Certolizumab pegol for hidradenitis suppurativa: case report and literature review. Dermatol Ther. 2020;33(6). DOI:https://doi.org/10.1111/dth.14494
   Google Scholar
• Esme P, Akoglu G, Caliskan E. Rapid response to certolizumab pegol in hidradenitis suppurativa: a case report. Ski Appendage Disord. 2021;7(1):58–61.
   PubMedGoogle Scholar
• Simponi (Golimumab) [Package Insert]. Horsham PA: Janssen Biotech, Inc.; 2020.
   Google Scholar
• Frampton JE. Golimumab: a review in inflammatory arthritis. BioDrugs. 2017;31(3):263–274.
   PubMed Web of Science ®Google Scholar
• Del M M-GM, Hamad J, Sayed C. Golimumab for the treatment of hidradenitis suppurativa in patients with previous TNF-α Treatment Failure. J Invest Dermatol. 2021;141(12):2975–2979.
   PubMedGoogle Scholar
• Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with crohn’s disease: more than 5 Years of follow-up in the TREATTM registry. Am J Gastroenterol. 2012;107(9):1409–1422.
   PubMed Web of Science ®Google Scholar
• Holcomb ZE, Porter ML, Kimball AB. A safety review of biologic therapies for the management of hidradenitis suppurativa and unmet needs. Expert Opin Drug Saf. 2021;20(10):1147–1161.
   PubMed Web of Science ®Google Scholar
• Fletcher JM, Moran B, Petrasca A, et al. IL-17 in inflammatory skin diseases psoriasis and hidradenitis suppurativa. Clin Exp Immunol. 2020;201(2):121–134.
   PubMed Web of Science ®Google Scholar
• Warren RB, Blauvelt A, Bagel J, et al. Bimekizumab versus Adalimumab in plaque psoriasis. N Engl J Med. 2021;385(2):130–141.
   PubMed Web of Science ®Google Scholar
• Glatt S, Jemec GBE, Forman S, et al. Efficacy and safety of bimekizumab in moderate to severe hidradenitis suppurativa. JAMA Dermatol. 2021;157(11):1279. DOI:https://doi.org/10.1001/jamadermatol.2021.2905.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials. Gov. A Study to Test the Long-Term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa (BE HEARD EXT). Identifier NCT04901195.
   Google Scholar
• ClinicalTrials. Gov. A Study to Test the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa (BE HEARD II). Identifier NCT04242498.
   Google Scholar
• ClinicalTrials. Gov. A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa (BE HEARD I). Identifier NCT04242446.
   Google Scholar
• Cosentyx (Secukinumab) [Package Insert]. East Hanover. New Jersey: Novartis Pharmaceuticals Corporation; 2021.
   Google Scholar
• Reguiaï Z, Fougerousse AC, Maccari F, et al. Effectiveness of secukinumab in hidradenitis suppurativa: an open study (20 cases). J Eur Acad Dermatol Venereol. 2020;34(11). DOI:https://doi.org/10.1111/jdv.16605
   Google Scholar
• Ribero S, Ramondetta A, Fabbrocini G, et al. Effectiveness of Secukinumab in the treatment of moderate–severe hidradenitis suppurativa: results from an Italian multicentric retrospective study in a real‐life setting. J Eur Acad Dermatol Venereol. 2021;35(7). DOI:https://doi.org/10.1111/jdv.17178
   Google Scholar
• Casseres RG, Prussick L, Zancanaro P, et al. Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: results of an open-label trial. J Am Acad Dermatol. 2020;82(6):1524–1526.
   PubMed Web of Science ®Google Scholar
• Prussick L, Rothstein B, Joshipura D, et al. Open‐label, investigator‐initiated, single‐site exploratory trial evaluating secukinumab, an anti‐interleukin‐17A monoclonal antibody, for patients with moderate‐to‐severe hidradenitis suppurativa. Br J Dermatol. 2019;181(3):609–611.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials. Gov. Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS) (SUNRISE). Identifier NCT03713632.
   Google Scholar
• ClinicalTrials. Gov. This Is a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS). SUNSHINE. Identifier NCT03713619.
   Google Scholar
• ClinicalTrials. Gov. Extension Study to Assess Effects of Non-Interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa. Identifier NCT04179175.
   Google Scholar
• Siliq (Brodalumab) [Package Insert]. Bridgewater, NJ: Valeant Pharmaceuticals. North America LLC; 2017.
   Google Scholar
• Frew JW, Navrazhina K, Grand D, et al. The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: an open-label cohort study. J Am Acad Dermatol. 2020;83(5):1341–1348.
   PubMed Web of Science ®Google Scholar
• Frew JW, Navrazhina K, Sullivan‐Whalen M, et al. Weekly administration of brodalumab in hidradenitis suppurativa: an open‐label cohort study. Br J Dermatol. 2021;184(2):350–352.
   PubMedGoogle Scholar
• ClinicalTrials. Gov. Molecular Characteristics of Brodalumab in Hidradenitis Suppurativa. Identifier NCT04979520.
   Google Scholar
• ClinicalTrials. Gov. Treatment of Moderate Hidradenitis Suppurativa. Identifier NCT03910803.
   Google Scholar
• Taltz (Ixekizumab). Package Insert. Indianapolis IN: Eli Lilly and Company; 2016.
   Google Scholar
• Cotter C, et al. Severe refractory hidradenitis suppurativa: treatment with ixekizumab, two case reports. Br J Dermatol. Available from: https://doi.org/10.1111/bjd.16406 [abstract] . 2018 Jul;179(Suppl. 1): 70 abstr. P100.
   Google Scholar
• Reardon K, Levin J, Levin C. Severe hidradenitis suppurativa with herpes simplex virus 1 superinfection and clinical responsiveness to ixekizumab. JAAD Case Rep. 2021;9:7–8.
   PubMedGoogle Scholar
• Megna M, Ruggiero A, Di Guida A, et al. Ixekizumab: an efficacious treatment for both psoriasis and hidradenitis suppurativa. Dermatol Ther. 2020;33(4). DOI:https://doi.org/10.1111/dth.13756
   Google Scholar
• Kaul M, Jarvis P, Rozenberg I, et al. First‐in‐human study demonstrating the safety and clinical efficacy of novel anti‐IL‐17A monoclonal antibody CJM112 in moderate to severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2021;35(5):1143–1151.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials. Gov. Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients. Identifier NCT02421172.
   Google Scholar
• Kashetsky N, Mufti A, Alabdulrazzaq S, et al. Treatment Outcomes of IL-17 Inhibitors in Hidradenitis Suppurativa: a Systematic Review. J Cutan Med Surg. Published online August 8, 2021;120347542110356. DOI:https://doi.org/10.1177/12034754211035667
   Google Scholar
• Armstrong AW, Read CP. Clinical presentation, and treatment of psoriasis. JAMA. 2020;323(19):1945.
   PubMed Web of Science ®Google Scholar
• Schlapbach C, Hänni T, Yawalkar N, et al. Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa. J Am Acad Dermatol. 2011;65(4):790–798.
   PubMed Web of Science ®Google Scholar
• Tremfya (Guselkumab) [Package Insert]. Horsham PA: Janssen Biotech, Inc.; 2020.
   Google Scholar
• ClinicalTrials. Gov. A study to evaluate the efficacy, safety, and tolerability of guselkumab for the treatment of participants with moderate to severe Hidradenitis Suppurativa (HS) (NOVA). Identifier NCT03628924.
   Google Scholar
• ClinicalTrials. Gov. Guselkumab for Hidradenitis Suppurativa, a Mode of Action Study. (HiGUS). Identifier NCT04061395.
   Google Scholar
• Skyrizi (Risankizumab-Rzaa) [Package Insert]. North Chicago IL: AbbVie Inc.; 2021.
   Google Scholar
• ClinicalTrials. Gov. A global study comparing risankizumab to placebo in adult participants with moderate to severe hidradenitis suppurativa (DETERMINED 1). Identifier NCT03926169.
   Google Scholar
• Caposiena Caro RD, Pensa C, Lambiase S, et al. Risankizumab effectiveness in a recalcitrant case of hidradenitis suppurativa after anti‐TNF and anti‐interleukin‐17 failures. Dermatol Ther. 2021;34(6). DOI:https://doi.org/10.1111/dth.15116
   Google Scholar
• Flora A, Holland R, Smith A, et al. Rapid and sustained remission of synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome with IL-23p19 antagonist (risankizumab). JAAD Case Rep. 2021;14:33–36.
   PubMedGoogle Scholar
• Licata G, Gambardella A, Buononato D, et al. A case of moderate hidradenitis suppurativa and psoriasis successfully treated with risankizumab. Int J Dermatol. Published online June 20, 2021. DOI:https://doi.org/10.1111/ijd.15704.
   Google Scholar
• Marques E, Arenberger P, Smetanová A, et al. Successful treatment of recalcitrant hidradenitis suppurativa with risankizumab after failure of anti‐tumour necrosis factor alpha. Br J Dermatol. 2021;184(5):966–967.
   PubMedGoogle Scholar
• Ilumya (Tildrakizumab-Asmn) [Package Insert]. Whitehouse Station NJ: Merck & Co., Inc.; 2018.
   Google Scholar
• Kok Y, Nicolopoulos J, Dolianitis C. Tildrakizumab as a potential long‐term therapeutic agent for severe hidradenitis suppurativa: a 15 months experience of an Australian institution. Australas J Dermatol. 2021;62(2). DOI:https://doi.org/10.1111/ajd.13559. .
   Google Scholar
• Stelara (Ustekinumab) [Package Insert]. Horsham PA: Janssen Biotech, Inc.; 2018.
   Google Scholar
• Blok JL, Li K, Brodmerkel C, et al. Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum. Br J Dermatol. 2016;174(4):839–846.
   PubMed Web of Science ®Google Scholar
• Valenzuela-Ubiña S, Jiménez-Gallo D, Villegas-Romero I, et al. Effectiveness of ustekinumab for moderate-to-severe hidradenitis suppurativa: a case series. J Dermatolog Treat. Published online June 11, 2020;1–4. doi:https://doi.org/10.1080/09546634.2020.1776208.
   Google Scholar
• Montero-Vilchez T, Pozo-Román T, Sánchez-Velicia L, et al. Ustekinumab in the treatment of patients with hidradenitis suppurativa: multicenter case series and systematic review. J Dermatolog Treat. Published online April 21, 2020;1–6. doi:https://doi.org/10.1080/09546634.2020.1755008.
   Google Scholar
• Romaní J, Vilarrasa E, Martorell A, et al. Ustekinumab with intravenous infusion: results in hidradenitis suppurativa. Dermatology. 2020;236(1):21–24.
   PubMed Web of Science ®Google Scholar
• Sánchez‐Martínez EM, García‐Ruiz R, Moneva‐Léniz LM, et al. Effectiveness and safety of ustekinumab in patients with hidradenitis suppurativa using intravenous induction. Dermatol Ther. 2020;33(6). DOI:https://doi.org/10.1111/dth.14054
   Google Scholar
• Crowley JJ, Warren RB, Cather JC. Safety of selective IL ‐23p19 inhibitors for the treatment of psoriasis. J Eur Acad Dermatol Venereol. 2019;33(9):1676–1684.
   PubMed Web of Science ®Google Scholar
• Del Duca E, Morelli P, Bennardo L, et al. Cytokine pathways and investigational target therapies in hidradenitis suppurativa. Int J Mol Sci. 2020;21(22):8436.
   Google Scholar
• Gottlieb A, Natsis NE, Kerdel F, et al. A phase II open-label study of bermekimab in patients with hidradenitis suppurativa shows resolution of inflammatory lesions and pain. J Invest Dermatol. 2020;140(8):1538–1545.e2.
   PubMed Web of Science ®Google Scholar
• Kanni T, Argyropoulou M, Spyridopoulos T, et al. MABp1 targeting IL-1α for moderate to severe hidradenitis suppurativa not eligible for Adalimumab: a randomized study. J Invest Dermatol. 2018;138(4):795–801.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials. Gov. A study to evaluate the efficacy, safety and tolerability of bermekimab in patients with hidradenitis suppurativa. Identifier NCT04019041.
   Google Scholar
• ClinicalTrials. Gov. A study of bermekimab for the treatment of participants with moderate to severe hidradenitis suppurativa (LYRA). Identifier NCT04988308.
   Google Scholar
• Kineret (Anakinra) [Package Insert]. Stockholm Sweden: Swedish Orphan Biovitrum AB; 2016.
   Google Scholar
• Leslie KS, Tripathi SV, Nguyen TV, et al. An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa. J Am Acad Dermatol. 2014;7(2):243–251.
   Google Scholar
• Tzanetakou V, Kanni T, Giatrakou S, et al. Safety and efficacy of anakinra in severe hidradenitis suppurativa. JAMA Dermatol. 2016;152(1):52. DOI:https://doi.org/10.1001/jamadermatol.2015.3903.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Assessment of the safety, tolerability and efficacy of MEDI8968 in subjects with moderate to severe hidradenitis suppurativa. Identifier NCT01838499.
   Google Scholar
• Ilaris (Canakinumab) [Package Insert]. East Hanover NJ: Novartis Pharmaceuticals Corporation; 2016.
   Google Scholar
• Jaeger T, Andres C, Grosber M, et al. Pyoderma gangrenosum and concomitant hidradenitis suppurativa – rapid response to canakinumab (anti-IL-1β). Eur J Dermatology. 2013;23(3):408–410. DOI:https://doi.org/10.1684/ejd.2013.2018
   PubMed Web of Science ®Google Scholar
• Houriet C, Seyed Jafari SM, Thomi R, et al. Canakinumab for severe hidradenitis suppurativa. JAMA Dermatol. 2017;153(11):1195.
   PubMedGoogle Scholar
• Kullenberg T, Löfqvist M, Leinonen M, et al. Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes. Rheumatology. 2016;55(8):1499–1506.
   PubMed Web of Science ®Google Scholar
• Otezla (Apremilast) [Package Insert]. Summit NJ: Celgene Corporation; 2017.
   Google Scholar
• Eigler A, Siegmund B, Emmerich U, et al. Anti-inflammatory activities of cAMP-elevating agents: enhancement of IL-10 synthesis and concurrent suppression of TNF production. J Leukoc Biol. 1998;63(1):101–107.
   PubMed Web of Science ®Google Scholar
• Claveau D, Chen SL, O’Keefe S, et al. Preferential Inhibition of T Helper 1, but Not T Helper 2, Cytokines in Vitro by L-826,141 [4-{2-(3,4-Bisdifluromethoxyphenyl)-2-{4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl}-3-methylpyridine-1-oxide], a Potent and Selective Phosphodiesterase 4 Inhibitor. J Pharmacol Exp Ther. 2004;310(2):752–760.
   PubMedGoogle Scholar
• Vossen ARJV, van Doorn MBA, van der Zee HH, et al. Apremilast for moderate hidradenitis suppurativa: results of a randomized controlled trial. J Am Acad Dermatol. 2019;80(1):80–88.
   PubMed Web of Science ®Google Scholar
• Kerdel FR, Azevedo FA, Kerdel Don C, et al. Apremilast for the treatment of mild-to-moderate hidradenitis suppurativa in a prospective, open-label, phase 2 study. J Drugs Dermatol. 2019;18(2):170–176.
   PubMed Web of Science ®Google Scholar
• UNION therapeutics receives FDA Fast Track designation for oral orismilast for the treatment of moderate to severe atopic dermatitis. PR Newswire (Online). Published November 4, 2021. Accessed December 2, 2021. https://www.prnewswire.com/news-releases/union-therapeutics-receives-fda-fast-track-designation-for-oral-orismilast-for-the-treatment-of-moderate-to-severe-atopic-dermatitis-301416168.html
   Google Scholar
• ClinicalTrials. Gov. Orismilast for the Treatment of Mild to Severe Hidradenitis Suppurativa (OSIRIS). Identifier NCT04982432.
   Google Scholar
• Solimani F, Meier K, Ghoreschi K. Emerging Topical and Systemic JAK Inhibitors in Dermatology. Front Immunol. 2019;10:10.
   PubMedGoogle Scholar
• Schwartz DM, Kanno Y, Villarino A, et al. Erratum: JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2018;17(1):78–78.
   Web of Science ®Google Scholar
• ClinicalTrials. Gov. A study of the safety of INCB054707 in participants with hidradenitis suppurativa. identifier NCT03569371.
   Google Scholar
• ClinicalTrials. Gov. A placebo-controlled study of the safety of INCB054707 in participants with hidradenitis suppurativa. Identifier NCT03607487.
   Google Scholar
• ClinicalTrials. Gov. To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa. Identifier NCT04476043.
   Google Scholar
• Rinvoq (Upadacitinib) [Package Insert]. North Chicago IL: Abbvie Inc.; 2019.
   Google Scholar
• RINVOQ® (upadacitinib) Receives U.S. FDA approval for active psoriatic arthritis. Published December 14, 2021. Accessed December 16, 2021. https://news.abbvie.com/news/press-releases/rinvoq-upadacitinib-receives-us-fda-approval-for-active-psoriatic-arthritis.htm
   Google Scholar
• ClinicalTrials. Gov. A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms. Identifier NCT04430855.
   Google Scholar
• Xeljanz (Tofacitinib) [Package Insert]. New York NY: Pfizer, Inc.; 2018.
   Google Scholar
• U.S. FDA approves pfizer’s XELJANZ® (tofacitinib) for the treatment of active ankylosing spondylitis. Published December 14, 2021. Accessed December 16, 2021. https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-pfizers-xeljanzr-tofacitinib-treatment-0
   Google Scholar
• Savage KT, Santillan MR, Flood KS, et al. Tofacitinib shows benefit in conjunction with other therapies in recalcitrant hidradenitis suppurativa patients. JAAD Case Rep. 2020;6(2):99–102.
   PubMedGoogle Scholar
• ClinicalTrials. Gov. Tofacitinib for Immune Skin Conditions in Down Syndrome. Identifier NCT04246372.
   Google Scholar
• Setyawan J, Azimi N, Strand V, et al. Reporting of Thromboembolic Events with JAK Inhibitors: analysis of the FAERS Database 2010–2019. Drug Saf. 2021;44(8):889–897.
   PubMedGoogle Scholar
• He X, Chen X, Zhang H, et al. Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015–2018). Expert Opin Ther Pat. 2019;29(2):137–149.
   PubMed Web of Science ®Google Scholar
• Krueger JG, McInnes IB, Blauvelt A. Tyrosine kinase 2 and Janus kinase‒signal transducer and activator of transcription signaling and inhibition in plaque psoriasis. J Am Acad Dermatol. 2022;86(1):148–157.
   PubMed Web of Science ®Google Scholar
• Papp K, Gordon K, Thaçi D, et al. Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis. N Engl J Med. 2018;379(14):1313–1321.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials. Gov. A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Suppurativa. Identifier NCT04092452.
   Google Scholar
• Xu Z, Li P, Fan L, et al. The Potential Role of circRNA in Tumor Immunity Regulation and Immunotherapy. Front Immunol. 2018;9:9.
   PubMed Web of Science ®Google Scholar
• Grand D, Navrazhina K, Frew JW. Integrating complement into the molecular pathogenesis of hidradenitis suppurativa. Exp Dermatol. 2020;29(1):86–92.
   PubMed Web of Science ®Google Scholar
• Tavneos (Avacopan) [Package Insert]. Cincinnati OH: ChemoCentryx Inc.; 2021.
   Google Scholar
• ClinicalTrials.gov. Evaluation of safety and efficacy of avacopan in subjects with moderate to severe hidradenitis suppurativa (Aurora). Identifier NCT03852472.
   Google Scholar
• ChemoCentryx Announces Positive Topline Results of Phase II Aurora Clinical Trial of Avacopan in the Treatment of Hidradenitis Suppurativa (HS). ChemoCentryx. October 20, 2020. www.ir.chemocentryx.com/news-releases/news-release-details/chemocentryx-announces-positive-topline-results-phase-ii-aurora. Press release.
   Google Scholar
• Giamarellos‐Bourboulis EJ, Argyropoulou M, Kanni T, et al. Clinical efficacy of complement C5a inhibition by IFX‐1 in hidradenitis suppurativa: an open‐label single‐arm trial in patients not eligible for Adalimumab. Br J Dermatol. 2020;183(1):176–178.
   PubMed Web of Science ®Google Scholar
• InflaRx reports additional analysis of the SHINE Phase IIb results for IFX-1 in hidradenitis suppurativa. InflaRx. Press release. July 18, 2019; www.inflarx.de/Home/Investors/Press-Releases/07-2019-InflaRx-Reports-Additional-Analysis-of-the-SHINE-Phase-IIb-Results-for-IFX-1-in-Hidradenitis-Suppurativa-.html
   Google Scholar
• Bechara FG, Podda M, Prens EP, et al. Efficacy and safety of Adalimumab in conjunction with surgery in moderate to severe hidradenitis suppurativa: the SHARPS randomized clinical trial. JAMA Surg. 2021;156(11):1001. DOI:https://doi.org/10.1001/jamasurg.2021.3655.
   PubMed Web of Science ®Google Scholar
• Shanmugam VK, Mulani S, McNish S, et al. Longitudinal observational study of hidradenitis suppurativa: impact of surgical intervention with adjunctive biologic therapy. Int J Dermatol. 2018;57(1):62–69.
   PubMed Web of Science ®Google Scholar
• Patel KR, Lee HH, Rastogi S, et al. Association between hidradenitis suppurativa, depression, anxiety, and suicidality: a systematic review and meta-analysis. J Am Acad Dermatol. 2020;83(3):737–744.
   PubMed Web of Science ®Google Scholar
• Kokolakis G, Wolk K, Schneider-Burrus S, et al. Delayed diagnosis of hidradenitis suppurativa and its effect on patients and healthcare system. Dermatology. 2020;236(5):421–430.
   PubMed Web of Science ®Google Scholar